Skip to main content
. 2022 Oct 4;13:1010835. doi: 10.3389/fimmu.2022.1010835

Figure 5.

Figure 5

Systemic (A) and local adverse reactions (B) following intradermal or intramuscular-intradermal primary series. Data presented as percentage of individuals who reported any systemic or local adverse reactions.